Profile data is unavailable for this security.
About the company
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS); or Bardet-Biedl syndrome (BBS). It is evaluating setmelanotide in Phase II and III trials for the treatment of obesity due to variants in one of numerous genes associated with the MC4R pathway.
- Revenue in USD (TTM)77.43m
- Net income in USD-184.68m
- Incorporated2013
- Employees226.00
- LocationRhythm Pharmaceuticals Inc222 Berkeley Street, 12th Floor BostonBOSTON 02116United StatesUSA
- Phone+1 (857) 264-4280
- Fax+1 (857) 264-4299
- Websitehttp://www.rhythmtx.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vericel Corp | 197.52m | -3.18m | 2.28bn | 314.00 | -- | 9.97 | 1,453.58 | 11.53 | -0.0684 | -0.0684 | 4.15 | 4.72 | 0.6304 | 4.26 | 3.77 | 629,031.90 | -1.02 | -3.07 | -1.17 | -3.50 | 68.64 | 67.87 | -1.61 | -4.49 | 4.21 | -- | 0.0004 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Denali Therapeutics Inc | 330.53m | -145.22m | 2.30bn | 445.00 | -- | 2.17 | -- | 6.97 | -1.09 | -1.09 | 2.39 | 7.45 | 0.2529 | -- | -- | 742,766.30 | -11.11 | -14.98 | -13.37 | -17.71 | -- | -- | -43.94 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Vera Therapeutics Inc | 0.00 | -95.99m | 2.30bn | 51.00 | -- | 18.50 | -- | -- | -2.28 | -2.28 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.54 | -- | -74.10 | -- | -- | -- | -- | -- | -- | -- | 0.3291 | -- | -- | -- | -7.79 | -- | -- | -- |
| Geron Corp | 237.00k | -184.13m | 2.39bn | 141.00 | -- | 8.97 | -- | 10,103.81 | -0.3246 | -0.3246 | 0.0004 | 0.455 | 0.0008 | -- | 0.0988 | 1,680.85 | -62.99 | -51.32 | -92.09 | -64.90 | -- | -- | -77,690.72 | -19,949.13 | -- | -- | 0.2484 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Avidity Biosciences Inc | 9.56m | -212.22m | 2.45bn | 253.00 | -- | 4.08 | -- | 256.23 | -2.90 | -2.90 | 0.131 | 6.32 | 0.0151 | -- | -- | 37,786.56 | -33.49 | -31.61 | -37.40 | -34.45 | -- | -- | -2,219.88 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| TG Therapeutics Inc | 233.66m | 12.67m | 2.45bn | 264.00 | 1,124.65 | 14.98 | 190.34 | 10.49 | 0.0141 | 0.0141 | 1.61 | 1.06 | 0.8933 | -- | 9.15 | 885,087.10 | 4.84 | -62.87 | 6.09 | -80.06 | 93.95 | -- | 5.42 | -405.03 | 5.18 | 1.64 | 0.3842 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
| Corcept Therapeutics Incorporated | 482.38m | 106.14m | 2.48bn | 352.00 | 25.03 | 4.87 | 23.13 | 5.14 | 0.9542 | 0.9542 | 4.32 | 4.90 | 0.8007 | 0.9374 | 13.37 | 1,370,384.00 | 17.62 | 21.17 | 20.65 | 23.85 | 98.66 | 98.52 | 22.00 | 27.23 | 4.31 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Rhythm Pharmaceuticals Inc | 77.43m | -184.68m | 2.53bn | 226.00 | -- | 14.50 | -- | 32.62 | -3.19 | -3.19 | 1.34 | 2.86 | 0.2165 | 1.61 | 7.34 | 342,601.80 | -51.64 | -47.21 | -59.55 | -52.84 | 87.99 | -- | -238.52 | -681.38 | 5.43 | -- | 0.3847 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Celldex Therapeutics, Inc. | 6.88m | -141.43m | 2.59bn | 160.00 | -- | 5.12 | -- | 376.81 | -2.91 | -2.91 | 0.1421 | 7.68 | 0.0168 | -- | 4.63 | 43,018.75 | -34.56 | -29.65 | -36.80 | -31.42 | -- | -- | -2,054.76 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| PTC Therapeutics, Inc. | 927.56m | -579.22m | 2.62bn | 988.00 | -- | -- | -- | 2.82 | -7.69 | -7.69 | 12.28 | -11.66 | 0.5459 | 2.33 | 4.64 | 938,823.90 | -34.09 | -26.71 | -48.63 | -33.46 | 92.88 | 93.94 | -62.45 | -83.80 | 1.98 | -0.7975 | 1.72 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
| Neogen Corp | 929.24m | 1.57m | 2.65bn | 2.64k | 1,699.03 | 0.8434 | 22.51 | 2.86 | 0.0072 | 0.0072 | 4.29 | 14.52 | 0.2044 | 2.79 | 5.81 | 351,984.10 | 0.0345 | 3.44 | 0.0355 | 3.62 | 50.97 | 47.25 | 0.1685 | 7.77 | 2.66 | 1.40 | 0.2205 | 0.00 | 56.01 | 15.63 | -147.34 | -- | 25.71 | -- |
| Hims & Hers Health Inc | 872.00m | -23.55m | 2.68bn | 1.05k | -- | 7.76 | -- | 3.07 | -0.1131 | -0.1131 | 4.17 | 1.61 | 2.16 | 7.13 | 195.17 | 833,652.00 | -5.83 | -- | -7.02 | -- | 81.99 | -- | -2.70 | -- | 2.74 | -- | 0.00 | -- | 65.49 | -- | 64.15 | -- | -- | -- |
| CG Oncology Inc | 204.00k | -67.80m | 2.71bn | 61.00 | -- | -- | -- | 13,268.45 | -1.07 | -1.07 | 0.0032 | 2.91 | -- | -- | -- | 3,344.26 | -- | -- | -- | -- | -- | -- | -23,826.96 | -- | -- | -- | 0.002 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| MoonLake Immunotherapeutics | 0.00 | -36.01m | 2.74bn | 50.00 | -- | 5.23 | -- | -- | -0.7623 | -0.7623 | 0.00 | 8.20 | 0.00 | -- | -- | 0.00 | -14.61 | -- | -16.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Merus NV | 43.95m | -154.94m | 2.76bn | 172.00 | -- | 7.63 | -- | 62.79 | -2.99 | -2.99 | 0.8519 | 6.16 | 0.1056 | -- | 13.56 | 255,505.80 | -37.24 | -29.35 | -45.30 | -35.36 | -- | -- | -352.56 | -252.21 | -- | -- | 0.00 | -- | 5.68 | 2.75 | -18.10 | -- | -1.73 | -- |
Data as of May 01 2024. Currency figures normalised to Rhythm Pharmaceuticals Inc's reporting currency: US Dollar USD
68.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| PRIMECAP Management Co.as of 31 Dec 2023 | 8.05m | 13.39% |
| Baker Bros. Advisors LPas of 31 Dec 2023 | 6.40m | 10.64% |
| RA Capital Management LPas of 31 Dec 2023 | 5.33m | 8.86% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 4.99m | 8.30% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 3.82m | 6.36% |
| Perceptive Advisors LLCas of 01 Apr 2024 | 3.27m | 5.44% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 3.09m | 5.14% |
| Federated Global Investment Management Corp.as of 31 Dec 2023 | 2.31m | 3.84% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.21m | 3.67% |
| Polar Capital LLPas of 31 Dec 2023 | 1.75m | 2.91% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
